TG Therapeutics (TGTX) Competitors

Genmab A/S (NASDAQ:GMAB) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Is GMAB or TGTX more profitable?

Genmab A/S has a net margin of 36.30% compared to TG Therapeutics' net margin of -5.42%. Genmab A/S's return on equity of 16.78% beat TG Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
TG Therapeutics	-5.42%	-8.32%	-3.40%

Do analysts recommend GMAB or TGTX?

Genmab A/S currently has a consensus price target of $42.17, suggesting a potential upside of 83.65%. TG Therapeutics has a consensus price target of $40.67, suggesting a potential upside of 18.15%. Given Genmab A/S's higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
TG Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Does the media refer more to GMAB or TGTX?

In the previous week, TG Therapeutics had 12 more articles in the media than Genmab A/S. MarketBeat recorded 20 mentions for TG Therapeutics and 8 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.24 beat TG Therapeutics' score of 0.74 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of GMAB or TGTX?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in GMAB or TGTX?

TG Therapeutics received 494 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 76.33% of users gave TG Therapeutics an outperform vote while only 62.84% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 164 62.84%	Underperform Votes 97 37.16%
TG Therapeutics	Outperform Votes 658 76.33%	Underperform Votes 204 23.67%

Which has more volatility and risk, GMAB or TGTX?

Genmab A/S has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500.

Which has higher valuation and earnings, GMAB or TGTX?

Genmab A/S has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$21.53B	0.71	$1.14B	$1.74	13.20
TG Therapeutics	$264.79M	20.23	$12.67M	-$0.10	-344.20

Summary

Genmab A/S beats TG Therapeutics on 11 of the 19 factors compared between the two stocks.